By identifying potentially relevant interaction profiles beyond the well-established propranolol–ADRB2 axis, this work seeks to provide preliminary in silico evidence that may support the development of future experimental studies focused on the multi-target potential of nsBBs in breast cancer therapy. Here, ADRB2 is linked to breast cancer.